News & Updates

Show Multimedia Only

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

17 Nov 2024

Patients with stage III melanoma show inconsistent use of adjuvant immunotherapy despite its survival benefits, according to a study.

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

17 Nov 2024

Older men receiving aggressive prostate cancer treatment growing in number

16 Nov 2024 by

In the past 2 decades, more and more men have been overtreated for intermediate- and high-risk prostate cancer despite having limited life expectancy, according to a large study.

Older men receiving aggressive prostate cancer treatment growing in number

16 Nov 2024

IBD therapies not linked to increased cancer risk among patients with breast cancer history

16 Nov 2024

The risk of new or recurrent cancer related to inflammatory bowel disease (IBD) treatment does not appear to be elevated for IBD patients with a history of breast cancer, according to a large retrospective study.

IBD therapies not linked to increased cancer risk among patients with breast cancer history

16 Nov 2024

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

15 Nov 2024

The fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy equecabtagene autoleucel (eque-cel) appears to induce early, deep, and lasting responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to the results of the phase Ib/II FUMANBA-1 trial.

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

15 Nov 2024

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Study pinpoints factors affecting cervical cancer screening participation in Singapore

13 Nov 2024 by

Cervical cancer screening uptake remains suboptimal in Singapore, with uptake influenced by demographic factors, screening knowledge and awareness, health-related belief and behaviour, according to a study.

Study pinpoints factors affecting cervical cancer screening participation in Singapore

13 Nov 2024

Early smoking cessation boosts cancer survival

12 Nov 2024

Quitting smoking within 6 months after receiving a cancer diagnosis appears to confer survival benefits, according to a study.

Early smoking cessation boosts cancer survival

12 Nov 2024

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

12 Nov 2024 by

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

12 Nov 2024

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024 by

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024.

Aumolertinib ups PFS in EGFR-mutated NSCLC

08 Nov 2024

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

Socioeconomic status tied to low use of adjuvant immunotherapy in stage III melanoma

Older men receiving aggressive prostate cancer treatment growing in number

Older men receiving aggressive prostate cancer treatment growing in number

IBD therapies not linked to increased cancer risk among patients with breast cancer history

IBD therapies not linked to increased cancer risk among patients with breast cancer history

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

Equecabtagene autoleucel shows antitumour activity in heavily pretreated RRMM

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Study pinpoints factors affecting cervical cancer screening participation in Singapore

Study pinpoints factors affecting cervical cancer screening participation in Singapore

Early smoking cessation boosts cancer survival

Early smoking cessation boosts cancer survival

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

EFS benefit greater with perioperative vs neoadjuvant-only nivolumab in resectable NSCLC

Aumolertinib ups PFS in EGFR-mutated NSCLC

Aumolertinib ups PFS in EGFR-mutated NSCLC

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Original New Drug Application Approvals by US FDA (16-31 October 2024)